Richard J Daly Catalyst Pharmaceuticals, Inc. (CPRX) insider trading activity

Richard J Daly is President and CEO of CATALYST PHARMACEUTICALS, INC.. Currently has a direct ownership of 199,764 shares of CPRX, which is worth approximately $5.07 Million. The most recent transaction as insider was on May 30, 2025, when has been sold 70,000 shares (Common Stock, par value $0.001 per share) at a price of $24.86 per share, resulting in proceeds of $1,740,200. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 200K

25.95% 3M change

14.93% 12M change

Total Value Held $5.07 Million

Richard J Daly Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 30 2025	BUY Open market or private sale	$1,740,200 $24.86 p/Share	70,000 Added 25.95%	199,764 Common Stock, par valu...
Feb 14 2025	SELL Payment of exercise price or tax liability	-	1,574 Reduced 0.58%	269,764 Common Stock, par valu...
Feb 14 2025	BUY Exercise of conversion of derivative security	-	4,000 Added 1.45%	271,338 Common Stock, par valu...
Jan 02 2025	SELL Payment of exercise price or tax liability	-	10,600 Reduced 3.81%	267,338 Common Stock, par valu...
Jan 02 2025	BUY Exercise of conversion of derivative security	-	42,105 Added 13.16%	277,938 Common Stock, par valu...
Dec 27 2024	SELL Payment of exercise price or tax liability	-	324 Reduced 0.14%	235,833 Common Stock, par valu...
Dec 27 2024	BUY Exercise of conversion of derivative security	-	1,333 Added 0.56%	236,157 Common Stock, par valu...
Jun 04 2024	SELL Open market or private sale	$276,648 $15.97 p/Share	17,323 Reduced 6.87%	234,824 Common Stock, par valu...
Jun 04 2024	BUY Exercise of conversion of derivative security	$160,400 $4.01 p/Share	40,000 Added 13.69%	252,147 Common Stock, par valu...
Feb 15 2024	SELL Payment of exercise price or tax liability	-	1,186 Reduced 0.56%	212,147 Common Stock, par valu...
Feb 15 2024	BUY Exercise of conversion of derivative security	-	4,000 Added 1.84%	213,333 Common Stock, par valu...
Dec 27 2023	BUY Exercise of conversion of derivative security	-	1,333 Added 0.63%	209,333 Common Stock, par valu...
Dec 07 2023	BUY Exercise of conversion of derivative security	$67,800 $1.13 p/Share	60,000 Added 22.39%	208,000 Common Stock, par valu...
May 12 2023	BUY Exercise of conversion of derivative security	$39,500 $0.79 p/Share	50,000 Added 25.25%	148,000 Common Stock, par valu...
Feb 15 2023	BUY Exercise of conversion of derivative security	-	4,000 Added 3.92%	98,000 Common Stock, par valu...
Dec 06 2022	BUY Exercise of conversion of derivative security	-	1,334 Added 1.4%	94,000 Common Stock, par valu...
Aug 24 2022	BUY Exercise of conversion of derivative security	$101,200 $2.53 p/Share	40,000 Added 30.15%	92,666 Common Stock, par valu...
Jan 25 2022	BUY Exercise of conversion of derivative security	$167,500 $3.35 p/Share	50,000 Added 48.7%	52,666 Common Stock, par valu...
Dec 03 2021	BUY Exercise of conversion of derivative security	-	1,333 Added 33.33%	2,666 Common Stock, par valu...
Dec 22 2020	BUY Exercise of conversion of derivative security	-	1,333 Added 50.0%	1,333 Common Stock, par valu...

Also insider at

OPNT

OPIANT PHARMACEUTICALS, INC. Healthcare

Director

RJD

Richard J Daly

President and CEO

Coral Gables, FL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CPRX shares.

Notify only if

Value

Insider Trading

Get notified when an Catalyst Pharmaceuticals, Inc. insider buys or sells CPRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to CATALYST PHARMACEUTICALS, INC.

Track Activities on CPRX

Account